𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors

✍ Scribed by Hirotoshi Kikuchi; Tomohiko Setoguchi; Shinichiro Miyazaki; Masayoshi Yamamoto; Manabu Ohta; Kinji Kamiya; Takanori Sakaguchi; Hiroyuki Konno

Publisher
Springer
Year
2011
Tongue
English
Weight
593 KB
Volume
16
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Novel V600E BRAF mutations in imatinib-n
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
✍ Narasimhan P. Agaram; Grace C. Wong; Tianhua Guo; Robert G. Maki; Samuel Singer; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 462 KB

## Abstract __BRAF__ and __NRAS__ are commonly mutated in cancer and represent the most frequent genetic events in malignant melanoma. More recently, a subset of melanomas was shown to overexpress KIT and harbor __KIT__ mutations. Although most gastrointestinal stromal tumors (GISTs) exhibit activa

Systemic therapy for advanced gastrointe
Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib
✍ Edward J. Kim; Mark M. Zalupski πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 88 KB

## Abstract Progression on first‐line therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinib‐resistant GIST include agents that target KIT/PDGFR